It's the volume, stupid
This article was originally published in Scrip
Fear ruled the day again in biotech stock trading on 24 March over worries the Washington machine was seeking to seize control of the industry's pricing structure – a frenzy set off by a letter from three Democratic lawmakers sent late last week to Gilead Sciences over the pricing of its hepatitis C virus (HCV) medicine Sovaldi (sofosbuvir).
You may also be interested in...
It's uncertain whether Democratic presidential candidate Hillary Clinton's attempt at drug pricing reform would be viable, but it's one analysts say to take seriously because the first step could lead to more.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.